A sharp 18% fall in a month has pushed Sonic Healthcare’s yield to 7%. Has the risk-reward tipped in investors’ favour?

A high dividend yield ASX stock with high earnings growth potential supported by a solid balance sheet and disciplined capital allocation.

Sonic Healthcare Limited (ASX: SHL)

Sonic Healthcare Limited (ASX: SHL) is one of the top fundamentally strong healthcare ASX stocks with a high current annual partly franked dividend yield of 5.61% and current market capitalisation of $9.5B.

Sonic Healthcare had announced on 20 August 2026 its financial and operational review for the year ended at June 2026.

Revenue increased by 13%, supported by an organic growth of 5% to ~$10.9B.

SHL has delivered exceptional growth in advanced diagnostics, with Sonic Genetics (Australia) and Biovis (Germany) delivering 15% and 12% YoY growth, respectively.

The specialist referrals continued to outperform with a growth of 7% in Australian Pathology.

Currently, SHL is at the top 1 in 6 markets, with FY2026 patent consultations of $144M and 3,200 patient access points.

Geographical Performance

Geographically, the Germany segment has delivered a statutory growth of 43%, with an organic growth of 5% on constant currency bases.

This segment contributes 25% of the revenue mix, followed by:

• 20% from Australia

• 19% from the USA

• The rest is covered by 6 countries

Earnings and Balance Sheet

Underlying EBITDA grew by 11% YoY to ~$1.9B, with statutory EBITDA growth of 9%.

Underlying net profit rose by 17% YoY to $621M, and statutory net profit growth of 18%.

The underlying earnings per share are up 14% YoY to 125.6 cents per share, while the statutory earning per share jumped by 15% YoY to 123 cents per share.

Net interest bearing debt grew to ~$3B, with a gearing ratio of 25.9% and an interest coverage ratio of 10x.

They have reported a debt cover of 2.2x, with total equity reaching ~$8.5B.

SHL has maintained an investment grade balance sheet with selective synergistic acquisitions and share buybacks using surplus capital under regular consideration.

Dividend

Sonic Healthcare has a strong dividend distribution history with a high dividend payout ratio.

In the recent results, SHL has announced a final partly franked dividend of $0.63 per share, making the total dividend for FY26 $1.07 per share.

It has a record date of 3 September 2026 and a payment date of 17 September 2026.

Furthermore, Sonic is expected to maintain a dividend payout ratio of 70–80% of net profit, supported by future earnings growth.

Outlook

Sonic holds a relatively stable outlook with a fundamental growth driver to continue strong organic growth across key markets, supported by industry tailwinds.

SHL is focused on expanding its advanced diagnostics capabilities and direct to consumer offerings.

They are expected to continue the proven executing strategy in FY27 with progression in US operating review initiatives.

Sonic expects future benefits and synergy from its acquisitions.

SHL has given FY27 EBITDA guidance to be in the range of $1.9M–$2.0B, excluding the back office IT systems transformation cost of ~$30M.

Conclusion

Sonic Healthcare Limited is a fundamentally strong company with earnings growth outpacing the revenue growth, highlighting operating leverage, ongoing synergy realization, and disciplined capital management.

The digital and AI transformation improved the operating efficiency and productivity at all levels, from the back office, operations, and clinical work.

The German business is the key growth driver for the company with fast growing advanced diagnostics and a direct-to-consumer market.

SHL has a high dividend yield, providing a constant, stable source of income for the long term, highlighting strong business fundamentals and earning quality of the company.

Source: Company Announcement